A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer.

摘要: To determine the activity and toxicities of a low dose leucovorin (ldLV) plus fluorouracil (5-FU) regimen, combined with oxaliplatin administered fortnightly (modified FOLFOX-4), as first-line therapy for patients advanced gastric cancer. Patients were treated cycles 85 mg/m2 on day 1 LV 20 mg/m2, followed by 5-FU 400 bolus 22 hour continuous infusion 600 days – 2 every two week intervals. Forty-five enrolled in this study. Forty-two assessable response. One 42 demonstrated complete response, partial responses, overall response rate 50%. The median time to progression survival 7.7 months (95% CI: 3.6 11.9 months) 11.2 9.1 13.3 months), respectively. Major hematologic included grade anemia (39.7%), neutropenia (30.4%) 3 4 (10.9%). Twelve associated neutropenic fever. most com...